Benzodiazepines, which have been associated with an increased incidence of infections in the critically ill, also may increase the risk of community-acquired pneumonia, according to a recent report published in Thorax.
Benzodiazepines, which have been associated with an increased incidence of infections in the critically ill, also may increase the risk of community-acquired pneumonia (CAP) and mortality following pneumonia, according to a recent report published in Thorax.
In a case-control study of approximately 29,700 controls and 5,000 patients with CAP from a UK patient database (2001-2002), researchers investigated the association between benzodiazepines and CAP occurrence as well as the impact of the drugs on mortality in the patients with CAP.
Eneanya Obiora, Division of Epidemiology and Public Health, University of Nottingham, UK, and colleagues found that use of benzodiazepines was associated with an increased risk of pneumonia (OR=1.54; 95% CI, 1.42–1.67). Diazepam, lorazepam, and temazepam were all associated with an increased incidence of CAP. In addition, this drug class was associated with increased 30-day (HR=1.22; 95% CI, 1.06–1.39) and long-term mortality (HR=1.32; 95% CI, 1.19–1.47) in patients who had a prior diagnosis of CAP.
The authors of the study suggested that further research is needed to determine the immune safety profile of benzodiazepines.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More